GMAB · Genmab A/S ADS
Genmab A/S (GMAB)
What's happening
- GMAB is up 8.54% today, trading at $43.42. — Live quote
- It's trading within 3% of its 52-week low ($1512.00). (Finnhub fundamentals)
- Volume today (902,152) is running 7.3x its 3-month average. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 13 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $4.91 actual vs. $3.59 estimated (+36.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (26 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 24.9% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 19.1%. Finnhub fundamentals ↗
- Trailing 52-week price return is +25.1%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2025-12-30; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on GMAB
No accessible free API for these — links go to the source directly.
Financials
Institutional holders
SEC Form 13F filers holding GMAB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 4 most recent filings · covers 2025-12-16 to 2025-12-29
Recent transactions
- Most recent: GENMAB A/S (Reporting person) — Open market purchase of 1,052,806 shares on 2025-12-29.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| GENMAB A/S | Reporting person | Open market purchase | 2025-12-29 | 1,052,806 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-12-29 | GENMAB A/S | Reporting person | Open market purchase | 1,052,806 | $97.00 |
| 2025-12-29 | GENMAB A/S | Reporting person | Open market purchase | 75,867,199 | $97.00 |
| 2025-12-26 | GENMAB A/S | Reporting person | Open market purchase | 2,978 | $97.00 |
| 2025-12-26 | GENMAB A/S | Reporting person | Open market purchase | 142,610 | $97.00 |
| 2025-12-24 | GENMAB A/S | Reporting person | Open market purchase | 96,082 | $97.00 |
| 2025-12-23 | GENMAB A/S | Reporting person | Open market purchase | 561,042 | $97.00 |
| 2025-12-22 | GENMAB A/S | Reporting person | Open market purchase | 15,710 | $97.00 |
| 2025-12-19 | GENMAB A/S | Reporting person | Open market purchase | 66,264 | $97.00 |
| 2025-12-18 | GENMAB A/S | Reporting person | Open market purchase | 212,177 | $97.00 |
| 2025-12-17 | GENMAB A/S | Reporting person | Open market purchase | 150,795 | $97.00 |
| 2025-12-16 | GENMAB A/S | Reporting person | Open market purchase | 120,752 | $97.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-23 17:32 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2025-12-30 | 4 | 2025-12-26 | View on SEC.gov → |
| 2025-12-29 | 4 | 2025-12-22 | View on SEC.gov → |
| 2025-12-22 | 4 | 2025-12-18 | View on SEC.gov → |
| 2025-12-18 | 4 | 2025-12-16 | View on SEC.gov → |
Recent news
Headlines about GMAB (Genmab A/S ADS). Links open the publisher — we don’t host full articles.
-
Genmab (GMAB) Reports Positive Phase 3 RAINFOL-02 Trial Results for Ovarian Cancer Therapy
GuruFocus · 2026-10-23 -
Genmab stock surges 9% following positive phase 3 ovarian cancer trial results
Yahoo Finance · 2026-10-23 -
Genmab A/S Stock (GMAB) Moved Up by 7.86% on Oct 23: A Full Analysis
TradingKey · 2026-10-23 -
Genmab A/S (GMAB) Stock Price | Live Quotes & Charts | NASDAQ
Timothy Sykes · 2026-10-23 -
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Yahoo Finance · 2026-10-23 -
GMAB Nov 2026 50.000 call (GMAB261120C00050000) interactive stock chart – Yahoo Finance
Yahoo Finance Singapore · 2026-10-23 -
(GMAB) Movement as an Input in Quant Signal Sets
Stock Traders Daily · 2026-10-22 -
Review Of ESMO Abstracts (NASDAQ:GMAB)
Seeking Alpha · 2026-10-20
No headlines in this category right now — try “All”.